SFT2D2 and prostate cancer: Notably, when comparing the transcript levels of chimeric SFT2D2‐TBX19 RNA and parental TBX19 RNA using PCR standard amplification curves, the transcript number of parental TBX19 was 102–103 times higher than that of chimeric SFT2D2‐TBX19 in six prostate cancer cell lines (Figure S6A–F, Supporting Information).